Open AccessBullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
Author(s) -
Shinohara Yasutake,
Iijima Toshie,
Sakurai Shintaro,
Jojima Teruo,
Ohira Eriko,
Hayashi Shujiro,
Usui Isao,
Igawa Ken,
Aso Yoshimasa
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3047
Subject(s) - discontinuation , medicine , bullous pemphigoid , dipeptidyl peptidase 4 inhibitor , dipeptidyl peptidase 4 , dipeptidyl peptidase , pemphigoid , dermatology , gastroenterology , pharmacology , diabetes mellitus , immunology , endocrinology , type 2 diabetes mellitus , type 2 diabetes , antibody , biochemistry , chemistry , enzyme
Abstract We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation. Clinicians should carefully monitor the course of DPP‐4 inhibitor‐associated BP even after withdrawal of DPP‐4 inhibitor therapy, especially in very elderly patients.